Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Histones | 3 | 2018 | 371 | 1.26 | Why? |
| Extracellular Vesicles | 2 | 2021 | 607 | 1.06 | Why? |
| Extracellular Traps | 5 | 2020 | 1036 | 0.99 | Why? |
| Receptors, Cell Surface | 1 | 2021 | 586 | 0.66 | Why? |
| Proteomics | 1 | 2021 | 2481 | 0.40 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.40 | Why? |
| Biomarkers, Tumor | 1 | 2018 | 1314 | 0.37 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.36 | Why? |
| Citrullination | 2 | 2018 | 85 | 0.35 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.34 | Why? |
| Cell-Derived Microparticles | 2 | 2018 | 134 | 0.33 | Why? |
| Plasma | 1 | 2017 | 1809 | 0.33 | Why? |
| Genetic Predisposition to Disease | 1 | 2021 | 4027 | 0.31 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.30 | Why? |
| Neutrophils | 3 | 2018 | 5476 | 0.28 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 7868 | 0.24 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.24 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.23 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.23 | Why? |
| Factor XIII Deficiency | 1 | 2021 | 19 | 0.23 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.19 | Why? |
| Thromboplastin | 1 | 2021 | 275 | 0.19 | Why? |
| Protein-Arginine Deiminases | 1 | 2017 | 12 | 0.18 | Why? |
| Blood Specimen Collection | 1 | 2021 | 387 | 0.17 | Why? |
| Sweden | 2 | 2021 | 1969 | 0.16 | Why? |
| Endotoxemia | 1 | 2018 | 143 | 0.16 | Why? |
| Lipopolysaccharides | 2 | 2018 | 848 | 0.15 | Why? |
| Neoplasms | 3 | 2019 | 17251 | 0.14 | Why? |
| von Willebrand Factor | 1 | 2021 | 668 | 0.14 | Why? |
| Observer Variation | 1 | 2017 | 622 | 0.14 | Why? |
| Neutrophil Activation | 1 | 2018 | 510 | 0.14 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.14 | Why? |
| Genome-Wide Association Study | 1 | 2021 | 1648 | 0.13 | Why? |
| Microvessels | 1 | 2018 | 490 | 0.13 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.13 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.12 | Why? |
| Interleukin-8 | 1 | 2018 | 964 | 0.11 | Why? |
| Male | 13 | 2021 | 367725 | 0.11 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.11 | Why? |
| Female | 13 | 2021 | 380317 | 0.11 | Why? |
| Thrombosis | 4 | 2021 | 7504 | 0.11 | Why? |
| Adult | 9 | 2021 | 244371 | 0.11 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.10 | Why? |
| Humans | 19 | 2021 | 930598 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2021 | 3607 | 0.09 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.09 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.08 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.08 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2019 | 1996 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Aged | 7 | 2021 | 215776 | 0.06 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Factor XIII | 1 | 2021 | 13 | 0.06 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.05 | Why? |
| Factor V | 1 | 2021 | 52 | 0.05 | Why? |
| Immunity, Innate | 1 | 2019 | 6570 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Plasminogen Activator Inhibitor 1 | 1 | 2021 | 162 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2021 | 9659 | 0.05 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Factor VIII | 1 | 2021 | 229 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.04 | Why? |
| Dried Blood Spot Testing | 1 | 2021 | 383 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| Fibrinolysis | 1 | 2020 | 521 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.04 | Why? |
| Critical Illness | 1 | 2018 | 17281 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.03 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Endothelium, Vascular | 1 | 2020 | 1751 | 0.02 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.02 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
Thålin's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(96)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(113)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_